Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Cardiovascular

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1795323

Cover Image

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1795323

Quinidine Sulfate

PUBLISHED:
PAGES: 175 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF (Single User License)
USD 5850
PDF (Global License to Company and its Fully-owned Subsidiaries)
USD 17550

Add to Cart

Description

Table of Contents

Global Quinidine Sulfate Market to Reach US$1.3 Billion by 2030

The global market for Quinidine Sulfate estimated at US$1.1 Billion in the year 2024, is expected to reach US$1.3 Billion by 2030, growing at a CAGR of 2.9% over the analysis period 2024-2030. Malaria, one of the segments analyzed in the report, is expected to record a 2.2% CAGR and reach US$738.7 Million by the end of the analysis period. Growth in the Arrhythmias segment is estimated at 4.1% CAGR over the analysis period.

The U.S. Market is Estimated at US$303.8 Million While China is Forecast to Grow at 5.4% CAGR

The Quinidine Sulfate market in the U.S. is estimated at US$303.8 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$256.5 Million by the year 2030 trailing a CAGR of 5.4% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.2% and 2.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.6% CAGR.

Global Quinidine Sulfate Market - Key Trends & Drivers Summarized

What Role Does Quinidine Sulfate Play in Modern Cardiovascular Therapies?

Quinidine sulfate has long held its position as a key antiarrhythmic agent, primarily used in the treatment of atrial and ventricular arrhythmias. Derived from the cinchona bark, quinidine works by slowing electrical conduction in the heart, stabilizing rhythm, and preventing recurrent episodes of tachyarrhythmia. In clinical settings, it is most commonly administered orally in sulfate form due to its superior bioavailability and pharmacokinetics. Although its use has declined with the advent of newer antiarrhythmic drugs, it remains an essential agent for niche applications, particularly in patients who demonstrate intolerance or resistance to contemporary alternatives. Its use is also being revisited due to its efficacy in treating Brugada syndrome and certain forms of short QT syndrome.

Healthcare practitioners often prescribe quinidine sulfate in carefully titrated doses, especially for long-term rhythm maintenance therapy in atrial fibrillation patients. The drug is also indicated in the management of malaria caused by Plasmodium falciparum in resistant cases, where other quinine derivatives fail. This duality of use supports its inclusion on the WHO Model List of Essential Medicines, indicating its continued relevance in both cardiovascular and tropical disease pharmacotherapy. Current medical literature highlights its value in pediatric cardiology and rare genetic arrhythmias where precision-based treatment protocols are evolving.

What Are the Key Applications and End-Use Trends Supporting Its Market Relevance?

The global quinidine sulfate market is majorly driven by applications in hospitals, specialty cardiac care centers, and research institutions. The compound is supplied in oral and injectable formats, with the oral sulfate form dominating the outpatient segment. With increasing focus on arrhythmia management, particularly in geriatric patients with multiple comorbidities, the demand for quinidine-based regimens remains relevant. Furthermore, the rising use of pharmacogenomics to identify optimal drug pathways for atrial fibrillation and congenital syndromes has revitalized interest in older antiarrhythmic compounds, especially those with a well-documented safety profile like quinidine.

In terms of end-use dynamics, the compound is witnessing renewed demand in academic research and drug repositioning initiatives. Research efforts are examining the repositioning of quinidine sulfate for neuromuscular diseases such as ALS (Amyotrophic Lateral Sclerosis) and epilepsy, where it modulates sodium channels in unique ways. Veterinary applications are also under investigation, particularly for equine cardiac conditions. Additionally, global health initiatives targeting drug-resistant malaria strains in underdeveloped regions are driving government procurements through public health channels, giving the quinidine sulfate market a broader geographical and therapeutic reach than typically acknowledged.

How Are Regulations and Drug Supply Chains Shaping Market Expansion?

The regulatory landscape governing quinidine sulfate is characterized by stringent quality, dosage, and pharmacovigilance standards. In North America and Europe, its use is tightly controlled, often requiring cardiac monitoring due to the risk of QT prolongation and torsades de pointes. However, these regulations have not dampened its utility, particularly in regions with high incidence of congenital arrhythmias or where alternative therapies are economically unfeasible. Generic manufacturers in India, China, and Eastern Europe have contributed to the global supply chain, making quinidine sulfate accessible in emerging markets while also supporting international aid and health programs.

From a supply chain perspective, the market faces periodic challenges due to reliance on limited active pharmaceutical ingredient (API) suppliers. The extraction of quinidine from natural sources is complex, and synthetic production remains cost-intensive. These factors have contributed to price volatility in recent years. Despite this, government-backed essential medicine programs and inclusion in rare disease reimbursement frameworks in countries like Brazil, Indonesia, and South Africa are keeping the distribution channels active. Partnerships between NGOs and pharmaceutical suppliers are also expanding the footprint of quinidine sulfate into less commercialized, yet clinically dependent, regional markets.

What Is Driving the Growth of the Quinidine Sulfate Market?

The growth in the quinidine sulfate market is driven by several factors, most notably the resurgence in clinical interest for managing genetically triggered arrhythmias and rare cardiac syndromes. Rising incidences of atrial fibrillation globally, especially among aging populations, have created a parallel demand for diverse pharmacologic options beyond contemporary beta-blockers and calcium channel blockers. The renewed emphasis on personalized medicine is also leading to selective re-adoption of quinidine sulfate based on individual patient profiles and genetic markers that favor its efficacy.

Drug repurposing initiatives further support market growth, especially as researchers uncover its off-label potential in treating sodium-channel related neurological conditions. The market is additionally supported by its role in combating drug-resistant malaria in specific geographies, where it remains an effective and essential second-line treatment. Moreover, the cost advantage of quinidine sulfate over newer antiarrhythmic agents in certain public healthcare systems continues to reinforce its usage. With academic trials and institutional research exploring expanded use cases, the global market for quinidine sulfate is expected to maintain steady growth across therapeutic and geographic segments over the coming decade.

SCOPE OF STUDY:

The report analyzes the Quinidine Sulfate market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Disease Type (Malaria, Arrhythmias, Other Diseases)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 34 Featured) -

  • ALLURE REMEDIES PVT. LTD.
  • Aurobindo Pharma
  • Bennet Pharmaceuticals Ltd
  • Biophore India Pharmaceuticals Pvt. Ltd
  • Buchler GmbH
  • Cipla Ltd
  • Dr.?Reddy's Laboratories Ltd
  • Intas Pharmaceuticals
  • Ipca Laboratories Ltd
  • Lark Laboratories India Ltd
  • Merck & Co., Inc.
  • Merck KGaA
  • Mylan N.V. (Viatrus/Mylan)
  • Novartis AG
  • Pfizer Inc.
  • Sanofi S.A.
  • Skymax Laboratories
  • Strides Pharma
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

Show more
Product Code: MCP37853

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Quinidine Sulfate - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Incidence of Atrial Fibrillation and Cardiac Arrhythmias Drives Demand for Antiarrhythmic Drugs
    • Innovation in Extended-Release Formulations Strengthens Treatment Adherence
    • Growth in Rare Disease Treatment Protocols Throws the Spotlight on Quinidine's Broader Applications
    • Regulatory Reapprovals for Repurposed Molecules Promote Quinidine Use in Orphan Indications
    • Development of Digital Cardiology Platforms Enhances Drug Monitoring Capabilities
    • Increasing Availability of Compounded Quinidine Formulations Boosts Hospital-Based Prescriptions
    • Partnerships With Cardiologists Strengthen Protocol-Based Dosing Adoption
    • Growing Research on Genetic Markers in Drug Metabolism Supports Personalized Dosage Regimens
    • Focus on Drug-Drug Interaction Risk Management Promotes Safer Combination Therapies
    • Expansion of Quinidine Application in Neurological Disorders Broadens Therapeutic Potential
    • Regulatory Guidance on Narrow Therapeutic Index Drugs Drives Monitoring Standards
    • Innovation in Microdose and Pediatric Formulations Supports Specialty Market Penetration
    • Rising Emphasis on Labeling Accuracy and GMP Compliance Fuels Manufacturing Modernization
    • Collaboration With Pharmacovigilance Networks Improves Long-Term Safety Profiling
    • Growth in Availability of Online Pharmacies and Specialty Drug Distributors Enhances Market Reach
    • Entry Into Global Licensing Agreements Strengthens Regional Access Strategies
    • Increasing Interest in Drug Repositioning Accelerates Investment in Quinidine Research
    • Support for Cardiology Clinics and Hospital Networks Boosts Direct Engagement
    • Emergence of Drug Supply Shortage Mitigation Programs Promotes Production Scalability
    • Expansion of Clinical Trial Evidence Base Elevates Prescriber Confidence in Quinidine Use
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Quinidine Sulfate Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Quinidine Sulfate by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Quinidine Sulfate by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Quinidine Sulfate by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Malaria by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Malaria by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Malaria by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Arrhythmias by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Arrhythmias by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Arrhythmias by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Other Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Other Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Other Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Quinidine Sulfate Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 14: USA Recent Past, Current & Future Analysis for Quinidine Sulfate by Disease Type - Malaria, Arrhythmias and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 15: USA Historic Review for Quinidine Sulfate by Disease Type - Malaria, Arrhythmias and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 16: USA 16-Year Perspective for Quinidine Sulfate by Disease Type - Percentage Breakdown of Value Sales for Malaria, Arrhythmias and Other Diseases for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 17: Canada Recent Past, Current & Future Analysis for Quinidine Sulfate by Disease Type - Malaria, Arrhythmias and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 18: Canada Historic Review for Quinidine Sulfate by Disease Type - Malaria, Arrhythmias and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 19: Canada 16-Year Perspective for Quinidine Sulfate by Disease Type - Percentage Breakdown of Value Sales for Malaria, Arrhythmias and Other Diseases for the Years 2014, 2025 & 2030
  • JAPAN
    • Quinidine Sulfate Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 20: Japan Recent Past, Current & Future Analysis for Quinidine Sulfate by Disease Type - Malaria, Arrhythmias and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 21: Japan Historic Review for Quinidine Sulfate by Disease Type - Malaria, Arrhythmias and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 22: Japan 16-Year Perspective for Quinidine Sulfate by Disease Type - Percentage Breakdown of Value Sales for Malaria, Arrhythmias and Other Diseases for the Years 2014, 2025 & 2030
  • CHINA
    • Quinidine Sulfate Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 23: China Recent Past, Current & Future Analysis for Quinidine Sulfate by Disease Type - Malaria, Arrhythmias and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 24: China Historic Review for Quinidine Sulfate by Disease Type - Malaria, Arrhythmias and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 25: China 16-Year Perspective for Quinidine Sulfate by Disease Type - Percentage Breakdown of Value Sales for Malaria, Arrhythmias and Other Diseases for the Years 2014, 2025 & 2030
  • EUROPE
    • Quinidine Sulfate Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 26: Europe Recent Past, Current & Future Analysis for Quinidine Sulfate by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 27: Europe Historic Review for Quinidine Sulfate by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 28: Europe 16-Year Perspective for Quinidine Sulfate by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 29: Europe Recent Past, Current & Future Analysis for Quinidine Sulfate by Disease Type - Malaria, Arrhythmias and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 30: Europe Historic Review for Quinidine Sulfate by Disease Type - Malaria, Arrhythmias and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 31: Europe 16-Year Perspective for Quinidine Sulfate by Disease Type - Percentage Breakdown of Value Sales for Malaria, Arrhythmias and Other Diseases for the Years 2014, 2025 & 2030
  • FRANCE
    • Quinidine Sulfate Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 32: France Recent Past, Current & Future Analysis for Quinidine Sulfate by Disease Type - Malaria, Arrhythmias and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 33: France Historic Review for Quinidine Sulfate by Disease Type - Malaria, Arrhythmias and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 34: France 16-Year Perspective for Quinidine Sulfate by Disease Type - Percentage Breakdown of Value Sales for Malaria, Arrhythmias and Other Diseases for the Years 2014, 2025 & 2030
  • GERMANY
    • Quinidine Sulfate Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 35: Germany Recent Past, Current & Future Analysis for Quinidine Sulfate by Disease Type - Malaria, Arrhythmias and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Germany Historic Review for Quinidine Sulfate by Disease Type - Malaria, Arrhythmias and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 37: Germany 16-Year Perspective for Quinidine Sulfate by Disease Type - Percentage Breakdown of Value Sales for Malaria, Arrhythmias and Other Diseases for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 38: Italy Recent Past, Current & Future Analysis for Quinidine Sulfate by Disease Type - Malaria, Arrhythmias and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Italy Historic Review for Quinidine Sulfate by Disease Type - Malaria, Arrhythmias and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 40: Italy 16-Year Perspective for Quinidine Sulfate by Disease Type - Percentage Breakdown of Value Sales for Malaria, Arrhythmias and Other Diseases for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Quinidine Sulfate Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 41: UK Recent Past, Current & Future Analysis for Quinidine Sulfate by Disease Type - Malaria, Arrhythmias and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 42: UK Historic Review for Quinidine Sulfate by Disease Type - Malaria, Arrhythmias and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 43: UK 16-Year Perspective for Quinidine Sulfate by Disease Type - Percentage Breakdown of Value Sales for Malaria, Arrhythmias and Other Diseases for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 44: Spain Recent Past, Current & Future Analysis for Quinidine Sulfate by Disease Type - Malaria, Arrhythmias and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Spain Historic Review for Quinidine Sulfate by Disease Type - Malaria, Arrhythmias and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 46: Spain 16-Year Perspective for Quinidine Sulfate by Disease Type - Percentage Breakdown of Value Sales for Malaria, Arrhythmias and Other Diseases for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 47: Russia Recent Past, Current & Future Analysis for Quinidine Sulfate by Disease Type - Malaria, Arrhythmias and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Russia Historic Review for Quinidine Sulfate by Disease Type - Malaria, Arrhythmias and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 49: Russia 16-Year Perspective for Quinidine Sulfate by Disease Type - Percentage Breakdown of Value Sales for Malaria, Arrhythmias and Other Diseases for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 50: Rest of Europe Recent Past, Current & Future Analysis for Quinidine Sulfate by Disease Type - Malaria, Arrhythmias and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Rest of Europe Historic Review for Quinidine Sulfate by Disease Type - Malaria, Arrhythmias and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 52: Rest of Europe 16-Year Perspective for Quinidine Sulfate by Disease Type - Percentage Breakdown of Value Sales for Malaria, Arrhythmias and Other Diseases for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Quinidine Sulfate Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 53: Asia-Pacific Recent Past, Current & Future Analysis for Quinidine Sulfate by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 54: Asia-Pacific Historic Review for Quinidine Sulfate by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 55: Asia-Pacific 16-Year Perspective for Quinidine Sulfate by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 56: Asia-Pacific Recent Past, Current & Future Analysis for Quinidine Sulfate by Disease Type - Malaria, Arrhythmias and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Asia-Pacific Historic Review for Quinidine Sulfate by Disease Type - Malaria, Arrhythmias and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 58: Asia-Pacific 16-Year Perspective for Quinidine Sulfate by Disease Type - Percentage Breakdown of Value Sales for Malaria, Arrhythmias and Other Diseases for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Quinidine Sulfate Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 59: Australia Recent Past, Current & Future Analysis for Quinidine Sulfate by Disease Type - Malaria, Arrhythmias and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Australia Historic Review for Quinidine Sulfate by Disease Type - Malaria, Arrhythmias and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 61: Australia 16-Year Perspective for Quinidine Sulfate by Disease Type - Percentage Breakdown of Value Sales for Malaria, Arrhythmias and Other Diseases for the Years 2014, 2025 & 2030
  • INDIA
    • Quinidine Sulfate Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 62: India Recent Past, Current & Future Analysis for Quinidine Sulfate by Disease Type - Malaria, Arrhythmias and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: India Historic Review for Quinidine Sulfate by Disease Type - Malaria, Arrhythmias and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 64: India 16-Year Perspective for Quinidine Sulfate by Disease Type - Percentage Breakdown of Value Sales for Malaria, Arrhythmias and Other Diseases for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 65: South Korea Recent Past, Current & Future Analysis for Quinidine Sulfate by Disease Type - Malaria, Arrhythmias and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 66: South Korea Historic Review for Quinidine Sulfate by Disease Type - Malaria, Arrhythmias and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 67: South Korea 16-Year Perspective for Quinidine Sulfate by Disease Type - Percentage Breakdown of Value Sales for Malaria, Arrhythmias and Other Diseases for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 68: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Quinidine Sulfate by Disease Type - Malaria, Arrhythmias and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Rest of Asia-Pacific Historic Review for Quinidine Sulfate by Disease Type - Malaria, Arrhythmias and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 70: Rest of Asia-Pacific 16-Year Perspective for Quinidine Sulfate by Disease Type - Percentage Breakdown of Value Sales for Malaria, Arrhythmias and Other Diseases for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Quinidine Sulfate Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 71: Latin America Recent Past, Current & Future Analysis for Quinidine Sulfate by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 72: Latin America Historic Review for Quinidine Sulfate by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 73: Latin America 16-Year Perspective for Quinidine Sulfate by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 74: Latin America Recent Past, Current & Future Analysis for Quinidine Sulfate by Disease Type - Malaria, Arrhythmias and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Latin America Historic Review for Quinidine Sulfate by Disease Type - Malaria, Arrhythmias and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 76: Latin America 16-Year Perspective for Quinidine Sulfate by Disease Type - Percentage Breakdown of Value Sales for Malaria, Arrhythmias and Other Diseases for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 77: Argentina Recent Past, Current & Future Analysis for Quinidine Sulfate by Disease Type - Malaria, Arrhythmias and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Argentina Historic Review for Quinidine Sulfate by Disease Type - Malaria, Arrhythmias and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 79: Argentina 16-Year Perspective for Quinidine Sulfate by Disease Type - Percentage Breakdown of Value Sales for Malaria, Arrhythmias and Other Diseases for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 80: Brazil Recent Past, Current & Future Analysis for Quinidine Sulfate by Disease Type - Malaria, Arrhythmias and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Brazil Historic Review for Quinidine Sulfate by Disease Type - Malaria, Arrhythmias and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 82: Brazil 16-Year Perspective for Quinidine Sulfate by Disease Type - Percentage Breakdown of Value Sales for Malaria, Arrhythmias and Other Diseases for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 83: Mexico Recent Past, Current & Future Analysis for Quinidine Sulfate by Disease Type - Malaria, Arrhythmias and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Mexico Historic Review for Quinidine Sulfate by Disease Type - Malaria, Arrhythmias and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 85: Mexico 16-Year Perspective for Quinidine Sulfate by Disease Type - Percentage Breakdown of Value Sales for Malaria, Arrhythmias and Other Diseases for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 86: Rest of Latin America Recent Past, Current & Future Analysis for Quinidine Sulfate by Disease Type - Malaria, Arrhythmias and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Rest of Latin America Historic Review for Quinidine Sulfate by Disease Type - Malaria, Arrhythmias and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 88: Rest of Latin America 16-Year Perspective for Quinidine Sulfate by Disease Type - Percentage Breakdown of Value Sales for Malaria, Arrhythmias and Other Diseases for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Quinidine Sulfate Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 89: Middle East Recent Past, Current & Future Analysis for Quinidine Sulfate by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 90: Middle East Historic Review for Quinidine Sulfate by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 91: Middle East 16-Year Perspective for Quinidine Sulfate by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 92: Middle East Recent Past, Current & Future Analysis for Quinidine Sulfate by Disease Type - Malaria, Arrhythmias and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Middle East Historic Review for Quinidine Sulfate by Disease Type - Malaria, Arrhythmias and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 94: Middle East 16-Year Perspective for Quinidine Sulfate by Disease Type - Percentage Breakdown of Value Sales for Malaria, Arrhythmias and Other Diseases for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 95: Iran Recent Past, Current & Future Analysis for Quinidine Sulfate by Disease Type - Malaria, Arrhythmias and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Iran Historic Review for Quinidine Sulfate by Disease Type - Malaria, Arrhythmias and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 97: Iran 16-Year Perspective for Quinidine Sulfate by Disease Type - Percentage Breakdown of Value Sales for Malaria, Arrhythmias and Other Diseases for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 98: Israel Recent Past, Current & Future Analysis for Quinidine Sulfate by Disease Type - Malaria, Arrhythmias and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Israel Historic Review for Quinidine Sulfate by Disease Type - Malaria, Arrhythmias and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 100: Israel 16-Year Perspective for Quinidine Sulfate by Disease Type - Percentage Breakdown of Value Sales for Malaria, Arrhythmias and Other Diseases for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 101: Saudi Arabia Recent Past, Current & Future Analysis for Quinidine Sulfate by Disease Type - Malaria, Arrhythmias and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Saudi Arabia Historic Review for Quinidine Sulfate by Disease Type - Malaria, Arrhythmias and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 103: Saudi Arabia 16-Year Perspective for Quinidine Sulfate by Disease Type - Percentage Breakdown of Value Sales for Malaria, Arrhythmias and Other Diseases for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 104: UAE Recent Past, Current & Future Analysis for Quinidine Sulfate by Disease Type - Malaria, Arrhythmias and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: UAE Historic Review for Quinidine Sulfate by Disease Type - Malaria, Arrhythmias and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 106: UAE 16-Year Perspective for Quinidine Sulfate by Disease Type - Percentage Breakdown of Value Sales for Malaria, Arrhythmias and Other Diseases for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 107: Rest of Middle East Recent Past, Current & Future Analysis for Quinidine Sulfate by Disease Type - Malaria, Arrhythmias and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Rest of Middle East Historic Review for Quinidine Sulfate by Disease Type - Malaria, Arrhythmias and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 109: Rest of Middle East 16-Year Perspective for Quinidine Sulfate by Disease Type - Percentage Breakdown of Value Sales for Malaria, Arrhythmias and Other Diseases for the Years 2014, 2025 & 2030
  • AFRICA
    • Quinidine Sulfate Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 110: Africa Recent Past, Current & Future Analysis for Quinidine Sulfate by Disease Type - Malaria, Arrhythmias and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Africa Historic Review for Quinidine Sulfate by Disease Type - Malaria, Arrhythmias and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 112: Africa 16-Year Perspective for Quinidine Sulfate by Disease Type - Percentage Breakdown of Value Sales for Malaria, Arrhythmias and Other Diseases for the Years 2014, 2025 & 2030

IV. COMPETITION

Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!